Latest studies
- RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseJapan - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseJapan - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseJapan - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This study is testing a new drug, rilvegostomig, against a standard treatment, pembrolizumab, for advanced lung cancer. It's for people whose cancer has spread and has high levels of a specific marker called PD-L1. The aim is to see which treatment works better and is safer.
Carcinoma, Non-Small Cell LungJapan - RecruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
Metastatic Colorectal CancerJapan - RecruitingPHASE2, PHASE3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine, icotrokinra, for people in the UK with moderately to severely active Crohn's disease. Researchers want to see if it helps reduce symptoms and if it's safe to use, compared to a dummy medicine.
Crohn DiseaseJapan - RecruitingPHASE3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
This study compares a new treatment, TAR-210, with standard chemotherapy for high-risk bladder cancer that hasn't spread to the muscle. It aims to see which treatment best prevents the cancer from returning or getting worse.
Non-Muscle Invasive Bladder NeoplasmsJapan - RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
Advanced Breast CancerJapan - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerJapan - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
Non Small Cell Lung CancerJapan - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseJapan - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaJapan - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisJapan - Active not recruitingPHASE2
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
This study is testing a new medicine called tarlatamab for people with a type of lung cancer called Small Cell Lung Cancer (SCLC) that has come back or not responded to previous treatments. It aims to see how safe and effective the new medicine is.
Relapsed/Refractory Small Cell Lung CancerJapan - Active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
Small Cell Lung Cancer (SCLC)Japan - Active not recruitingPHASE3
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
This study is looking at a new medicine called romosozumab for children and teenagers aged 5-17 with Osteogenesis Imperfecta (brittle bone disease). It wants to see if romosozumab is better than existing bisphosphonate medicines at preventing broken bones and improving bone strength over 12 months.
Osteogenesis ImperfectaJapan - RecruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)Japan - Active not recruitingPHASE3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
This study looks at a new drug, apalutamide, combined with standard hormone therapy for men with high-risk prostate cancer before and after surgery. It aims to see if this combination helps shrink the cancer more and prevents it from spreading, compared to hormone therapy alone.
Prostatic NeoplasmsJapan - RecruitingPHASE1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
This study is testing a new medicine, JNJ-88549968, for people with specific types of blood cancers called myeloproliferative neoplasms (MPNs) that have a CALR gene mutation. It aims to find the safest dose and see how well it works, sometimes given with other existing treatments.
NeoplasmsJapan - RecruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
Relapsed Refractory Multiple Myeloma (RRMM)Japan - Active not recruitingPHASE3
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
This study looks at a new treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread. It compares this new treatment alongside standard care to standard care alone, aiming to see if it helps patients live longer without their cancer getting worse.
Prostatic NeoplasmsJapan - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
This study looks at two different daily pill combinations for adults newly diagnosed with HIV. It compares a two-drug treatment with a three-drug treatment to see which is safer and works better for controlling the virus.
HIVHIV InfectionsJapan - Active not recruitingPHASE3
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
This study looks at a new inhaled medicine, molgramostim, for a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP). We want to see if it helps patients better than a dummy treatment. After 48 weeks, everyone gets the active medicine.
Autoimmune Pulmonary Alveolar ProteinosisJapan - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaJapan - Active not recruiting
Micra Transcatheter Pacing System Post-Approval Registry
This study is looking at how a tiny pacemaker, the Micra Transcatheter Pacing System, works in everyday life after it's been approved. It's for people who need this type of pacemaker due to a slow heart rate (bradycardia) to check its safety and how well it works over time.
BradycardiaJapan - Active not recruitingPHASE1
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
This study is looking into a new medicine, ABBV-101, for blood cancers called non-Hodgkin's lymphoma (NHL). It will check how safe the medicine is, how it moves through the body, and if it helps people with different types of NHL that have come back or not responded to other treatments.
Hematologic CancerJapan - RecruitingPHASE2, PHASE3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This study keeps an eye on people who have had a special treatment called gene-modified T-cell therapy for cancer. It aims to check their health and how well the treatment worked over a long time, making sure it's safe and effective.
NeoplasmsJapan - Active not recruitingPHASE3
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This study is testing a new combination treatment for a type of bladder cancer that hasn't spread deep into the bladder wall. It's comparing a new drug called Durvalumab with the standard treatment to see if it's more effective and safe.
Non-muscle-invasive Bladder CancerJapan - RecruitingPHASE3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
This study looks at the long-term safety and how well a medicine called belimumab works for people with lung problems linked to certain conditions like lupus. It's for people who've already been in a previous study.
Connective Tissue DiseasesJapan - RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
Prostate Cancer MetastaticJapan - RecruitingPHASE3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
This study compares a new medicine, deucravacitinib, with an existing one, ustekinumab, for long-term safety in people with moderate to severe plaque psoriasis. It focuses on participants who also have heart disease risk factors.
Plaque PsoriasisJapan - Active not recruitingPHASE3
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
This study looks at a new drug, tucatinib, combined with T-DM1 to treat advanced HER2-positive breast cancer. It aims to see if this combination works better than T-DM1 alone for cancer that has spread or can't be removed by surgery.
HER2-positive Breast CancerJapan - RecruitingPHASE2
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is for adults with certain advanced cancers, including small cell lung cancer. It tests a new treatment called BI 764532 to see if different doses are safe and can shrink tumours. Sometimes, this treatment is called obrixtamig.
Small Cell Lung CarcinomaNeuroendocrine NeoplasmsExtra-pulmonary Neuroendocrine CarcinomaJapan - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Afimkibart for people with moderately to severely active Crohn's disease. It's a Phase 3 study, which means it's a big step before the medicine might become widely available, looking at how well it works and if it's safe.
Moderately to Severely Active Crohns DiseaseJapan - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
Colorectal NeoplasmsJapan - RecruitingPHASE3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
This study looks at a new medicine called Tozorakimab. We want to see if it can help people in hospital with lung infections who need extra oxygen. The goal is to stop them from getting sicker, like needing a breathing machine, or even dying.
Viral Lung Infection and Acute Respiratory FailureJapan - RecruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
Multiple MyelomaJapan - RecruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
Carcinoma, Non-Small-Cell LungNeoplasm MetastasisJapan - Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersJapan - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
Non-small Cell Lung Cancer (NSCLC)Japan - RecruitingPHASE3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
This study looks at how best to treat a type of cancer called germ cell tumours in children and adults. It compares simply watching the tumour after surgery with different chemotherapy treatments to see which works best and causes fewer side effects.
Childhood Extracranial Germ Cell TumorExtragonadal Embryonal CarcinomaGerm Cell TumorMalignant Germ Cell TumorJapan - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseJapan - Active not recruitingPHASE3
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
This study looks at two different medicines, T-DXd and T-DM1, for certain people with HER2-positive breast cancer. It's for those who still have some cancer after their first treatments. We want to see if T-DXd works better at stopping the cancer from coming back.
HER2-Positive Primary Breast CancerResidual Invasive Breast CancerJapan - Active not recruitingPHASE3
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, apalutamide, for men with prostate cancer that hasn't spread but is resistant to standard treatment. It aims to see if the drug can stop the cancer from spreading and if it's safe to use.
Prostatic NeoplasmsJapan - RecruitingPHASE3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This study looks at the long-term safety of a new medicine, KarXT, for people with changes in their thoughts and feelings due to Alzheimer's disease. Participants have already taken part in similar studies and will continue to be monitored for about a year.
Psychosis Associated With Alzheimer's DiseaseJapan - RecruitingPHASE3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study looks at a new way to give a cancer drug called tislelizumab for advanced stomach cancer. We're comparing injections under the skin to drips into a vein, alongside usual chemotherapy. We want to see if the injection works just as well and is easier for patients.
Metastatic Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaJapan - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This study is testing a new combination of medicines, Giredestrant and Palbociclib, for advanced breast cancer. It's for people whose cancer is hormone-sensitive (ER-positive) but not HER2-positive. Researchers want to see if this new combination works better and is safer than a standard treatment.
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerJapan - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
Metastatic Prostate CancerProstate AdenocarcinomaJapan - Active not recruitingPHASE3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This study is testing a new medicine, BLU-5937, for adults in the UK with a long-lasting cough that hasn't responded to other treatments. It aims to see if the medicine can reduce how often people cough over 24 weeks, compared to a dummy pill.
CoughRefractory Chronic CoughJapan - Active not recruitingPHASE3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
This study is comparing two ways of giving a medicine called amivantamab for advanced lung cancer. One is through a drip, and the other is a new injection under the skin. We want to see if the injection is easier and quicker for patients.
Advanced or Metastatic Non-small Cell Lung CancerJapan